image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

News Releases
View All
Events
March 14, 2023 from 10:40 AM to 11:10 AM EDT
Oppenheimer 33rd Annual Healthcare Conference
View Webcast
February 21, 2023 from 1:00 PM to 1:45 PM EST
Wells Fargo Targeted Protein Degradation Virtual Summit
View Webcast
February 21, 2023 from 8:00 AM to 8:45 AM EST
Wells Fargo Targeted Protein Degradation Virtual Summit
View Webcast
View All

SEC Filings

Filing date Description Form View

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 DEF 14A View HTML
0001140361-23-013573.pdf
0001140361-23-013573.rtf
0001140361-23-013573.xls

Additional proxy soliciting materials - definitive

 DEFA14A View HTML
0001140361-23-013574.pdf
0001140361-23-013574.rtf
0001140361-23-013574.xls
View All

Corporate Profile

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents.
 
Learn more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Print Page
Email Alerts
RSS Feeds
Contact IR